XZP 5610
Alternative Names: XZP-5610Latest Information Update: 28 Jun 2024
At a glance
- Originator XuanZhu Pharma
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action Farnesoid X-activated receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in China (PO, Tablet)
- 31 May 2021 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in China (PO) (NCT04913090)
- 27 Jan 2021 NMPA approves the clinical trial application of XZP 5610 for Non-alcoholic steatohepatitis, in China